Get the Stockscreener App
0.449
4.31%
-0.0202
Pre-market:
.45
0.001
+0.22%
Scilex Holding Company stock is traded at $0.449, with a volume of 1.20M.
It is down -4.31% in the last 24 hours and down -11.00% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$0.4692
Open:
$0.4738
24h Volume:
1.20M
Relative Volume:
0.56
Market Cap:
$71.96M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-0.3481
EPS:
-1.29
Net Cash Flow:
$-21.04M
1W Performance:
-1.23%
1M Performance:
-11.00%
6M Performance:
-76.97%
1Y Performance:
-73.74%
1-Day Range:
$0.431
$0.4738
1-Week Range:
$0.4005
$0.525
52-Week Range:
$0.38
$2.63
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
0.449 | 71.96M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Alliance Global Partners | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-16-23 | Initiated | B. Riley Securities | Buy |
| Oct-13-23 | Initiated | B. Riley Securities | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
Scilex Holding Company Stock (SCLX) Latest News
Scilex Holding Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scilex Holding Company (SCLX) reports earnings - Quartz
Jane Street Group LLC Trims Position in Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - Yahoo Finance
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch - The Manila Times
Scilex (NASDAQ:SCLXW) Trading Up 22.5% – Here’s Why - Defense World
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Thinking about buying stock in Scilex Holding, iCoreConnect, Genius Group, Helius Medical Technologies, or TradeUP Acquisition? - Marketscreener.com
**Scilex Holding Co Changes Record Date for Dividend Payment**** - Defense World
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, - The Manila Times
Scilex Holding Shifts Semnur Pharmaceuticals Dividend Record Date to January 2025, Updates Preferred Stock Distribution - StockTitan
Scilex Holding (NASDAQ:SCLX) Short Interest Down 14.0% in December - Defense World
Scilex Holding (NASDAQ:SCLX) Sees Large Decline in Short Interest - MarketBeat
State Street Corp Buys 54,404 Shares of Scilex Holding (NASDAQ:SCLX) - Defense World
Scilex (NASDAQ:SCLXW) Shares Up 4.7% – What’s Next? - Defense World
Scilex CEO Jaisim Shah buys $13,800 in company stock By Investing.com - Investing.com South Africa
Scilex CEO Jaisim Shah buys $13,800 in company stock - Investing.com India
Jaisim Shah Purchases 30,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
SCLX stock touches 52-week low at $0.46 amid market challenges - Investing.com
Scilex Holding Co options imply 15.0% move in share price post-earnings - TipRanks
Palo Alto pharmaceutical company secures $17M - The Business Journals
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Scilex Holding Company closes registered direct offering - Medical Buyer
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - The Manila Times
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Scilex completes $17 million direct stock and warrant offering - Investing.com
Scilex Holding Co options imply 17.2% move in share price post-earnings - TipRanks
Scilex secures $17 million in stock and warrant sale - Investing.com
Scilex Holding Company Announces $17 Million Registered Direct Offering - The Manila Times
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - The Manila Times
Scilex Bio says KDS201 currently enrolling with U.S. patient cohort to be added - TipRanks
Scilex Bio, a Controlling Interest of Joint Venture by - GlobeNewswire
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - Yahoo Finance
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials C - The Manila Times
NeuroBiogen Company and Scilex Bio Enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 - Marketscreener.com
SCLX: Deal Brings Huge Potential - Research Tree
Scilex Holding agrees to share sale to meet debt obligations By Investing.com - Investing.com Nigeria
Scilex Holding agrees to share sale to meet debt obligations - Investing.com
Scilex Announces Joint Venture for CNS Compound Development - TipRanks
NeuroBiogen Company and Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company enter into Binding Term Sheet for Worldwide License, Along with the Rights to Sublicense for All of KDS2010 indications; Binding Term Sheet Includes C - The Manila Times
NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - The Manila Times
Scilex and IPMC announce joint venture for obesity drug By Investing.com - Investing.com UK
Scilex Holding Company Enters into a Binding Term Sheet for - GlobeNewswire
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Short Interest in Scilex Holding (NASDAQ:SCLX) Decreases By 51.1% - MarketBeat
Scilex Holding Co reaches agreement to waive default penalties By Investing.com - Investing.com South Africa
Scilex receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):